Squarepoint
FTH icon

Squarepoint’s Faeth Therapeutics FTH Stock Holding History

Squarepoint’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$761K Buy
+25,582
New +$796K ﹤0.01% 3021

Other funds holding FTH

UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
RIS
Richmond Investment Services Mequon, Wisconsin $316M AUM 19.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Freestone Capital Holdings
Freestone Capital Holdings Seattle, Washington $3.8B AUM 20.96% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
State of Wyoming
State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return
Financial Consulate
Financial Consulate Hunt Valley, Maryland $899M AUM 14.82% 1-Year Est. Return

Squarepoint's FTH Position: Q3 2026 in Review

Squarepoint opened a new position in Faeth Therapeutics (FTH) in Q3 2026: 25,582 shares worth $761K. The stake represents ﹤0.01% of the portfolio and ranks #3021 among its holdings.

14 funds tracked by Wall St. Rank hold FTH as of Q3 2026.

  • Squarepoint held 25,582 shares of Faeth Therapeutics worth $761K as of Q3 2026.
  • Faeth Therapeutics was a new Squarepoint position in Q3 2026.
  • Faeth Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #3021 holding.
  • 14 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.